Drug intelligence / Profile preview

CL-Long-750

Development stage: Preclinical
Lead developer: Stephenson Cancer Center
Modality: Peptides
Administration: Intravenous

Overview

CL-Long-750 is a peptide-based diagnostic imaging probe designed to target Claudin-4, a protein highly expressed in triple-negative breast cancer (TNBC), pancreatic cancer, and other malignancies. The probe consists of a 30-amino acid peptide derived from the C-terminal fragment of *Clostridium perfringens* enterotoxin (CPE) conjugated to a HiLite 750 nm fluorescent dye. It is utilized for the identification of tumors via multispectral optoacoustic tomography (MSOT) and near-infrared fluorescence (NIRF) imaging. Research indicates that CL-Long-750 exhibits superior binding and signal intensity compared to shorter variants, facilitating the rapid detection of claudin-4-positive cells.

Other names: Claudin-4 probeClaudin4 probeClaudin 4 probe

Targets

CLDN4 (Claudin-4)

Beyond the preview

Go deeper on CL-Long-750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-Long-750.

Explore the full profile